July 25, 2014 11:24 PM ET


Company Overview of InfaCare Pharmaceutical Corporation

Company Overview

InfaCare Pharmaceutical Corporation, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceuticals for the neonatal and pediatric patient population. Its neonatal product, Stanate, is under development for the pharmacologic treatment of infantile jaundice or hyperbilirubinemia. The company was founded in 2005 and is based in Trevose, Pennsylvania.

8 Neshaminy Interplex

Suite 221

Trevose, PA 19053-6499

United States

Founded in 2005





Key Executives for InfaCare Pharmaceutical Corporation

Chief Executive Officer
Age: 62
Founder and Chairman
Age: 70
Chief Financial Officer
Board Observer
Compensation as of Fiscal Year 2014.

Similar Private Companies By Industry

Company Name Region
Valley Nuclear Incorporated United States
Herbalife International of America, Inc. United States
Boca Pharmacal, Inc. United States
TAXIS Pharmaceuticals, Inc. United States
ONO Pharma USA, Inc. United States

Recent Private Companies Transactions

Private Placement
June 4, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact InfaCare Pharmaceutical Corporation, please visit infacare.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.